The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Published at www.nejm.org March 31, 2003 (10.1056/NEJMoa030634)

Identification of Severe Acute Respiratory Syndrome in Canada
Susan M. Poutanen, M.D., M.P.H., Donald E. Low, M.D., Bonnie Henry, M.D., Sandy Finkelstein, M.D., David Rose, M.D., Karen Green, R.N., Raymond Tellier, M.D., Ryan Draker, B.Sc., Dena Adachi, M.Sc., Melissa Ayers, B.Sc., Adrienne K. Chan, M.D., Danuta M. Skowronski, M.D., M.H.Sc., Irving Salit, M.D., Andrew E. Simor, M.D., Arthur S. Slutsky, M.D., Patrick W. Doyle, M.D., Mel Krajden, M.D., Martin Petric, M.D., Robert C. Brunham, M.D., M.H.Sc., Allison J. McGeer, M.D., for the National Medical Laboratory, Canada, and the Canadian SARS Study Team

 Sign up for free e-toc
 

This Article
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Severe acute respiratory syndrome (SARS) is a condition of unknown cause that has recently been recognized in patients in Asia, North America, and Europe. This report summarizes the initial epidemiologic findings, clinical description, and diagnostic findings that followed the identification of SARS in Canada.

Methods SARS was first identified in Canada in early March 2003. We collected epidemiologic, clinical, and diagnostic data from each of the first 10 cases prospectively as they were identified. Specimens from all cases were sent to local, provincial, national, and international laboratories for studies to identify an etiologic agent.

Results The patients ranged from 24 to 78 years old; 60 percent were men. Transmission occurred only after close contact. The most common presenting symptoms were fever (in 100 percent of cases) and malaise (in 70 percent) followed by nonproductive cough (in 100 percent) and dyspnea (in 80 percent) associated with infiltrates on chest radiography (in 100 percent). Lymphopenia (in 89 percent of those for whom data were available), elevated lactate dehydrogenase levels (in 80 percent), elevated aspartate aminotransferase levels (in 78 percent), and elevated creatinine kinase levels (in 56 percent) were common. Empirical therapy most commonly included antibiotics, oseltamivir, and intravenous ribavirin. Mechanical ventilation was required in five patients. Three patients died, and five have had clinical improvement. The results of laboratory investigations were negative or not clinically significant except for the amplification of human metapneumovirus from respiratory specimens from five of six patients and from one asymptomatic contact of a patient with SARS. A novel coronavirus was isolated and amplified from respiratory specimens from five of six patients. In four cases both pathogens were isolated.

Conclusions SARS is a condition associated with substantial morbidity and mortality. It appears to be of viral origin, with patterns suggesting droplet or contact transmission. The role of human metapneumovirus, a novel coronavirus, or both requires further investigation.

Notice: Because of possible public health implications, this article has been published at www.nejm.org on March 31, 2003.

Click on "PDF of this article" for the full text.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.